PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
LabMan @ $KZIA - Stock Twits
research from Harvard, Dana Farber & MGH- 2022 Mar;10(3):e003402. doi: 10.1136/jitc-2021-003402. "PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment" Imminent Harvard data releases, highlight high stakes for pAX. "We found that expression of a catalytically active mutation in phospho-inositol 3 kinase (PI3K ..confers a selective growth advantage to tumors treated with immunotherapy that is revered by pharmacological PI3K inhibition"
pAX maybe considered as a future general purpose PI3K therapy, targeted to overcome resistance in combo with current mainstream cancer drugs. It functions by inhibiting(repair) the damaged, cancer proliferated, enzyme carrying human pathway & complements other treatments, not to compete on efficacy. Distinguish targeted therapy and the way they work, from typical randomization, new drug verse standard therapy. The mechanism of PI3K in combo is understood, it now not a case of OS verse existing therapy"

https://pubmed.ncbi.nlm.nih.gov/35264433/

Regards.